Takeda Pharmaceutical (TAK) free cash flow

Free cash flow · fiscal 2026
¥626.77B

Takeda Pharmaceutical (TAK) generated free cash flow of ¥626.77B in fiscal 2026 (the year ended March 31, 2026). That is 7.5% lower than the ¥677.56B of fiscal 2025. Figures as of 18 Nov 2026, 12:26 UTC, from Yahoo Finance.

Key facts

Free cash flow, fiscal 2026
¥626.77B
Change on fiscal 2025
−7.5%
Highest on record
¥677.56Bfiscal 2025
Lowest on record
¥235.61Bfiscal 2024
Fiscal years on record
42023–2026

Figures as of . Statements from Yahoo Finance. Amounts are in JPY. Figures, not advice.

Takeda Pharmaceutical free cash flow, in more detail

Across the 4 fiscal years on record (2023–2026), the highest was ¥677.56B in fiscal 2025 and the lowest ¥235.61B in fiscal 2024.

History · 4 fiscal years

Free cash flow by fiscal year

Takeda Pharmaceutical free cash flow, year by year

Takeda Pharmaceutical (TAK) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2026¥626.77B 7.5% down
2025¥677.56B 187.6% up
2024¥235.61B 31.4% down
2023¥343.47B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Takeda Pharmaceutical and comparable companies
CompanyFree cash flowFiscal year
Takeda Pharmaceutical TAK¥626.77B2026
Cencora COR$3.21B2025
Boston Scientific BSX$3.40B2025
Cardinal Health CAH$4.53B2026
argenx ARGX$573.51M2025
Edwards Lifesciences EW$1.34B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TAK

Takeda Pharmaceutical, figure by figure

Takeda Pharmaceutical (TAK) overview: price, valuation and scorecardAll health care companies by market value

Takeda Pharmaceutical free cash flow: questions and answers

What is Takeda Pharmaceutical's free cash flow?

Takeda Pharmaceutical (TAK) generated free cash flow of ¥626.77B in fiscal 2026 (the year ended March 31, 2026). That is 7.5% lower than the ¥677.56B of fiscal 2025.

What are the highest and lowest free cash flow figures on record for Takeda Pharmaceutical?

Across the 4 fiscal years on record (2023–2026), the highest was ¥677.56B in fiscal 2025 and the lowest ¥235.61B in fiscal 2024.

How is Takeda Pharmaceutical's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Takeda Pharmaceutical it is on record here for 4 fiscal years, 2023 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Takeda Pharmaceutical (TAK) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/TAK/free-cash-flow

Underlying data: Yahoo Finance.